Comparison of propofol, dexamedetomidine and their combination’s effect for sedation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001284

Enrollment

Registered

2014-11-25

Start date

2014-08-05

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Designated initial target effect site concentration (Ce) of propofol is infused through Orchestra® Base Primea TCI pump (Fresenius Kabi, Brezins, France). Loading dose of dexamedetomidine is in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who reqiure Brachial plexus block. American Society of Anesthesiologists’ classification from 1 to 3.

Exclusion criteria

Exclusion criteria: patients whe do not agree with the experiment. Patients with impaired cognitive function. Patients with serious neurological, cardiac, liver, and kidney disease.

Design outcomes

Primary

Measure	Time frame
the extent of loss of airway patent;The change of the blood pressure	—

Secondary

Measure	Time frame
bispectral index ;observer assessment of alertness/sedation (OAA/S) score;Heart rate ;oxygen saturation;end tidal carbon dioxide;respiratory rate ;hypoxia, spontaneous movement, cough, nausea, vomiting, agitation;Onset time of designated level of sedation and recovery time;satisfaction level and recall, nausea, vomiting	—

Countries

Korea, Republic of

Contacts

Public ContactKyu Kim

Hanyang University Seoul Hospital

vesicle100@naver.com

Outcome results